Cognition Therapeutics (NASDAQ:CGTX) Issues Earnings Results

Cognition Therapeutics (NASDAQ:CGTX) issued its quarterly earnings results on Thursday. The company reported ($0.17) EPS for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.01), Zacks reports. During the same period in the prior year, the business earned ($0.27) earnings per share.

Cognition Therapeutics Trading Up 0.5 %

CGTX opened at $0.43 on Friday. The company’s 50 day moving average is $0.59 and its 200-day moving average is $0.55. The company has a market cap of $17.82 million, a P/E ratio of -0.44 and a beta of 1.03. Cognition Therapeutics has a 1-year low of $0.34 and a 1-year high of $2.95.

Analyst Ratings Changes

CGTX has been the subject of a number of analyst reports. B. Riley upgraded Cognition Therapeutics from a “neutral” rating to a “buy” rating and upped their price target for the company from $1.00 to $1.50 in a research report on Thursday, December 19th. Chardan Capital reduced their price objective on Cognition Therapeutics from $11.00 to $8.00 and set a “buy” rating on the stock in a research note on Friday. HC Wainwright raised their price objective on Cognition Therapeutics from $5.00 to $6.00 and gave the stock a “buy” rating in a report on Thursday, December 19th. Finally, Brookline Capital Management upgraded shares of Cognition Therapeutics to a “strong-buy” rating in a research report on Monday, January 27th. One analyst has rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $7.70.

Cognition Therapeutics Company Profile

Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies.